Phase 3 Psoriatic Arthritis Trial, Recruiting NCT07295509 Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. Condition: Psoriatic Arthritis
Back to Psoriatic Arthritis

Phase 3 Psoriatic Arthritis Trial, Recruiting

NCT07295509
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 75 years
  • People who have been diagnosed with Psoriatic Arthritis (PsA) for at least 3 months, and who meet a standard set of classification criteria for PsA at the screening visit
  • People with currently active PsA, meaning at least 3 tender joints and at least 3 swollen joints at both the screening and baseline visits
  • People who currently have active plaque psoriasis (at least one skin lesion of 2cm or larger), nail psoriasis, or a documented history of plaque psoriasis
  • People whose PsA has not responded well enough to, or who could not tolerate, prior treatment with NSAIDs (common anti-inflammatory medicines) or non-biologic DMARDs (a type of disease-modifying medication)
  • People who are on a stable dose of any background medications permitted by the trial, if they are taking any

Who may not be able to join:

  • People who have other inflammatory conditions that could interfere with how the study drug is assessed
  • People who have previously been treated with more than 2 biologic medicines (a specific type of medication used for inflammatory conditions)
  • People who have recently used certain medications that are not permitted in this trial, as specific waiting periods between stopping those medications and joining the trial apply (confirm with trial site)
  • People who have forms of psoriasis other than plaque psoriasis, or whose psoriasis was caused by a medication
  • People who have severe, progressive, or uncontrolled conditions affecting the kidneys, liver, heart, lungs, digestive system, hormonal system, nervous system, blood, joints (other than PsA), mental health, or urinary system
  • People whose recent blood or laboratory test results show significant abnormalities
  • People who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 18361923769

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Registry
ClinicalTrials.gov
Start date
18 December 2025
Est. completion
31 December 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Percentage of participants who achieved an American College of Rheumatology (ACR) 20 response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov